Department of Health and Human Services, through National Institutes of Health, awarded Biotherapeutics, Inc. of Blacksburg, VA $500,000 under the SBIR program (Phase I), with work starting 2026-09-18 and running to 2027-09-17. It is one of 7 SBIR and STTR awards Biotherapeutics, Inc. received in the last two years, $2,464,685 in all. Each figure links to the federal record.
The award
| Recipient | Biotherapeutics, Inc. (Blacksburg, VA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $500,000 |
| Period of performance starts | 2026-09-18 |
| Period of performance ends | 2027-09-17 |
| Award number | R43AG102078 (grant, CFDA 93.866) |
| Assistance listing | 93.866, Aging Research |
| Place of performance | Blacksburg, Montgomery County, VA |
| Recipient registry id (UEI) | DKZNEQL174E3 |
Want the whole picture on Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
25 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Immunometabolic therapeutics for alzheimer's disease - immunometabolic therapeutics for alzheimer’s disease biotherapeutics inc (bti) is an emerging biotech company that synergistically combines the power of advanced com
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-18 | New | 000 | $500,000 |
Immunometabolic therapeutics for alzheimer's disease - immunometabolic therapeutics for alzheimer’s disease biotherapeutics inc (bti) is an emerging biotech company that synergistically combines the power of advanced computational modeling with translational experimentation to accelerate the development of novel precision medicine therapeutics for inflammatory, autoimmune and neurodegenerative diseases. This SBIR application will characterize a new immunometabolic therapeutic target for alzheimer’s disease (alz). Our product: With the goal of developing first-in-class oral therapeutics that protect against neurodegeneration in alz, bti has designed a novel chemotype that targets the immune and metabolic dysregulation in the brain. Our product candidates provide protection from alz by regulating lipid metabolism and glial cell activation. Background: Alz is a neurodegenerative disorder that afflicts an estimated 6 million people in the u.s. With over $300 billion annually in associated healthcare costs. The only recent therapeutic approvals have been met with controversy due to a lack of perceived clinical benefit in pivotal trials. Thus, there is an unmet clinical need for safe and efficacious alz therapeutics. While alz is commonly associated with β-amyloid plaques and neurofibrillary tangles, pathological features also include increased inflammation and oxidative stress, dama ...
From the federal award record.
Other SBIR and STTR awards to Biotherapeutics, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-01 | Department of Health and Human Services | SBIR Phase I | $314,363 | Immunometabolic therapeutics for multiple sclerosis - immunometabolic therapeutics for mul (record) |
| 2026-08-13 | Department of Health and Human Services | SBIR Phase I | $314,363 | Novel immunoregulatory therapeutics for bacterial gastritis - novel immunoregulatory thera (record) |
| 2025-08-13 | Department of Health and Human Services | SBIR Phase I | $314,363 | Next-gen oral therapeutics for concomitant clostridioides difficile infection and ibd - ne (record) |
| 2025-08-01 | Department of Health and Human Services | SBIR Phase I | $314,363 | Novel therapeutic for sle - novel therapeutic for sle biotherapeutics inc (bti) is a clini (record) |
| 2025-07-01 | Department of Health and Human Services | SBIR Phase I | $359,625 | Next-gen oral therapeutics for type 2 diabetes - next-gen oral therapeutics for type 2 dia (record) |
| 2025-02-01 | Department of Health and Human Services | SBIR Phase I | $347,608 | The next wave of asthma therapeutics - the next wave of asthma therapeutics biotherapeutic (record) |
Every other federal award to Biotherapeutics, Inc. on record
The federal register lists 18 other awards to the same registry id (UEI DKZNEQL174E3), $10,686,409 in all, from 2 agencies.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2024-09-20 | National Institutes of Health | $355,935 | Development of novel immunoregulatory therapeutics for asthma - development of novel immunoregulatory therapeu (R43HL172516) |
| 2024-08-20 | National Institutes of Health | $288,986 | Development of novel therapeutics for asthma - development of novel therapeutics for asthma biotherapeutics in (R43HL176386) |
| 2024-07-01 | National Institutes of Health | $300,000 | Comparative efficacy of therapeutics for clostridioides difficile infection - comparative efficacy of therapeu (R43AI184008) |
| 2023-09-20 | National Institutes of Health | $2,045,673 | A first-in-class topical immunoregulatory therapeutic for psoriasis - a first-in-class topical immunoregulator (R44AR083730) |
| 2023-09-20 | National Institutes of Health | $295,294 | A first-in-class topical immunoregulatory therapeutic for psoriasis - a first-in-class topical immunoregulator (R43AR083730) |
| 2023-09-07 | National Institutes of Health | $295,924 | Novel first-in-class therapeutics for rheumatoid arthritis - novel first-in-class therapeutics for rheumatoid (R43AR082207) |
| 2023-09-05 | National Institutes of Health | $295,924 | Development of novel topical therapeutics for psoriasis - development of novel topical therapeutics for psoria (R43AR082756) |
| 2023-04-15 | National Institutes of Health | $356,068 | Immunoregulatory therapeutics for ulcerative colitis - immunoregulatory therapeutics for ulcerative colitis bi (R43DK135158) |
| 2021-08-01 | National Institutes of Health | $361,510 | Targeting the immunometabolic hub NLRX1 as a novel therapeutic for asthma - targeting the immunometabolic hub (R43HL160260) |
| 2021-06-11 | National Institutes of Health | $300,000 | The first LANCL2-BASED therapeutic for influenza - the first LANCL2-BASED therapeutic for influenza biotherape (R43AI165190) |
| 2021-01-01 | National Institutes of Health | $1,127,318 | Novel immunoregulatory therapeutics for systemic lupus erythematosus - novel immunoregulatory drugs for system (R44AI156952) |
| 2021-01-01 | National Institutes of Health | $300,000 | Novel immunoregulatory therapeutics for systemic lupus erythematosus - novel immunoregulatory drugs for system (R43AI156952) |
| 2020-09-01 | National Institutes of Health | $295,453 | The first pomegranate seed oil-containing medical food for gut and immune health (R43AT010991) |
| 2020-07-29 | Defense Contract Management Agency | $555,620 | Computational modeling of immune responses to clostridium difficile infection for predicting therapeutic effic (HDTRA12010021) |
| 2019-07-01 | National Institutes of Health | $299,984 | Development of antibiotic-free clostridium difficile therapeutics (R43AI145361) |
| 2019-04-01 | National Institutes of Health | $1,634,902 | Effects of abscisic acid on insulin sensitivity (R44DK120338) |
| 2019-04-01 | National Institutes of Health | $1,278,242 | Validation of immunometabolic NLRX1 therapeutics for ibd (R44DK121561) |
| 2018-08-21 | National Institutes of Health | $299,576 | BT-11: A first-in-class oral therapeutic for inflammatory bowel disease (R44AI134163) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Biotherapeutics, Inc.Look up Biotherapeutics, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Biotherapeutics, Inc.Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.